We are live on ! Find out more
COGT icon

Cogent Biosciences
COGT

69 hedge funds and large institutions have $284M invested in Cogent Biosciences in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 11

2.06% more ownership

Funds ownership: 92.68% → 94.74% (+2.1%)

0% more funds holding

Funds holding: 69 → 69 (0)

0% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 19

6% less capital invested

Capital invested by funds: $303M → $284M (-$19.4M)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

Holders
69
Holders Change
–
Holders Change %
0%
% of All Funds
1.2%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.07%
New
19
Increased
18
Reduced
11
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$17.8M
2
CS
Candriam SCA
Luxembourg
+$12.1M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$7.36M
4
DM
Deerfield Management
New York
+$5.08M
5
State Street
State Street
Massachusetts
+$4.11M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$11.1M
2
Millennium Management
Millennium Management
New York
-$6.73M
3
SFM
Sphera Funds Management
Israel
-$6.7M
4
DCM
Driehaus Capital Management
Illinois
-$4.96M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$4.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$25.9M – – –
BlackRock
2
BlackRock
New York
$21.7M +$17.8M +2,109,352 +371%
Janus Henderson Group
3
Janus Henderson Group
United Kingdom
$19.8M +$1.31M +155,073 +7%
CS
4
Candriam SCA
Luxembourg
$15.5M +$12.1M +1,435,911 +302%
ABG
5
Ally Bridge Group
New York
$13.2M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$13M -$4.46M -527,454 -25%
DM
7
Deerfield Management
New York
$13M +$5.08M +601,000 +60%
GTC
8
Ghost Tree Capital
New York
$13M – – –
FFM
9
Fairmount Funds Management
Pennsylvania
$12.6M – – –
BI
10
BVF Inc
California
$12.4M – – –
Point72 Asset Management
11
Point72 Asset Management
Connecticut
$12M +$7.36M +871,595 +143%
LGM
12
Logos Global Management
California
$11.5M – – –
CC
13
Commodore Capital
New York
$11.1M +$831K +98,387 +8%
VA
14
VR Adviser
New York
$8.83M – – –
RCM
15
RA Capital Management
Massachusetts
$8.32M – – –
HA
16
HHLR Advisors
Cayman Islands
$8.11M – – –
AVAI
17
Atlas Venture Associates IX
Massachusetts
$7.44M – – –
PIM
18
Platinum Investment Management
Australia
$6.7M +$796K +94,216 +13%
Invesco
19
Invesco
Georgia
$5.92M +$226K +26,762 +4%
FCM
20
Farallon Capital Management
California
$4.87M – – –
Geode Capital Management
21
Geode Capital Management
Massachusetts
$4.65M +$2.76M +326,825 +132%
Axa
22
Axa
France
$4.6M -$6.76K -800 -0.1%
TCM
23
Tekla Capital Management
Massachusetts
$4.36M – – –
State Street
24
State Street
Massachusetts
$4.11M +$4.11M +486,657 +2,409%
Northern Trust
25
Northern Trust
Illinois
$2.77M +$2.38M +281,768 +468%
1
2 3 4

COGT Hedge Fund Activity: Q2 2021 in Review

69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q2 2021, worth a combined $284M — down 6.4% from $303M a quarter earlier.

Fund positioning in COGT was balanced in Q2 2021: 19 funds opened new positions, 19 closed out, 18 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, adding an estimated $17.8M. The largest seller was Citadel Advisors, exiting entirely with an estimated $11.1M sold.

  • 69 institutional investors held Cogent Biosciences (COGT) as of Q2 2021, unchanged from Q1 2021.
  • Funds reported $284M of Cogent Biosciences stock for Q2 2021, down 6.4% quarter-over-quarter.
  • 19 funds opened new Cogent Biosciences positions in Q2 2021 and 19 closed out, a net change of 0 holders.
  • The largest Cogent Biosciences buyer in Q2 2021 was BlackRock, an estimated $17.8M added.
  • The largest Cogent Biosciences seller in Q2 2021 was Citadel Advisors, an estimated $11.1M sold.

Based on aggregated 13F filings for Q2 2021.